Kornimate/medical-research-clean huggingface dataset:
patient activation intervention in improving screening rates for colorectal cancer

Conditions: Colon Cancer; Rectal Cancer

Summary: this randomized clinical trial focused on activating the patient to ask their health care provider for a colorectal cancer screening test to improve screening rates for colorectal cancer. the patient activation intervention may increase information seeking, number of screening tests ordered and number of completed screening tests for colorectal cancer.

primary objectives: i. to test a patient activation intervention to improve colorectal cancer (crc) screening rates using fecal occult blood test (fobt) among male and female patients 50 years and older from the east central columbus neighborhood health center. secondary objectives: i. to assess if there is a change in knowledge and attitudes about crc screening after watching the educational video. ii. to assess the effectiveness of providing communication skills training for improving discussion focusing on crc screening during the patient-provider visit. outline: patients are randomized to 1 of 2 arms prior to a medical visit. arm i (education only): patients receive crc and crc screening information by an educational video and a brochure with healthy hints to prevent crc. arm ii (education and patient activation): patients receive crc and crc screening information and communication skills training (patient activation) intervention by educational video and brochure and a brochure about healthy hints to prevent crc. after the medical visit, patients' medical records are reviewed at 1 month and 2 months after the visit to document crc screening completion.

Eligibility criteria:
inclusion criteria: * patient is 50+ years of age * patient is in need of crc screening * patient is in good health (e.g. no contraindications to having crc screening, such as a history of colorectal cancer, congenital heart failure, renal failure, dialysis, dementia, severe arthritis, etc.) * patient is not pregnant * patient is able to speak, read, and understand english exclusion criteria: * patient is within crc screening guidelines * patient is at high risk for crc * patient cannot understand english * patient cannot complete a crc screening test

Keywords: colon cancer colorectal cancer screening
the study of mechanism of alzheimer's disease using acupuncture based on fmri

Conditions: Alzheimer's Disease

Summary: alzheimer's disease (ad) is one of the major brain diseases which received more attention in recent years. the disconnection syndrome is the main pathophysiological mechanism leading to cognitive decline in ad patients. both animal experiment and clinical observation have demonstrated that acupuncture can generate treatment effect on ad patients by moderating the neural pathway directly. however, the underlying mechanism remains unclear. by using resting state functional magnetic resonance imaging (fmri) method, as well as acupuncture and neurology sciences, investigators will explore the multi-modality data analysis; compare brain connectivity and network parameters changes between pre- and post- acupuncture treatment; analyze the correlation between fmri changes and neuropsychology test. the present study aims to elucidate the neural mechanism of acupuncture therapy on early ad, provide theoretical evidence from the perspective of functional connectivity.


Eligibility criteria:
inclusion criteria: clinical diagnosis of alzheimer's disease clinical diagnosis of mci due to alzheimer's disease drug therapy regularly exclusion criteria: frontotemporal dementia lewy body dementia vascular dementia severe depression brain vascular disease metabolic disease
family-centered diabetes project

Conditions: Diabetes

Summary: the purpose of this project is to determine whether a diabetes lifestyle program will improve the lives of native american people living with diabetes. we recruited native american people living in 8 pueblo communities served by 3 indian health service clinics. forty percent of people living with diabetes in those communities participated in an interview and had height, weight, blood pressure and hemoglobin a1c measured at the beginning. then they received a lifestyle program in either groups or one-on-one, or another group which got the intervention after one year (comparison group). the program was developed using input from community members, tribal leaders, and clinic staff, and was taught by community members in or near the participating communities. after each session, participants were asked for feedback about the curriculum. after the program ended, the interview and clinical measures were repeated. feedback to tribal leaders and clinical staff is ongoing.


Eligibility criteria:
inclusion criteria: * male or female 18 years or older with diabetes living in a participating native american community served by one of three participating indian health service clinics. exclusion criteria: * unable to complete a yearly interviewer administered questionnaire and clinical measures of height, weight, blood pressure, and fingerstick hemoglobin a1c. * unable to participate in 5 lifestyle intervention meetings occurring over a one year period.

Keywords: diabetes lifestyle intervention native american community intervention diet exercise
augmented reality mobile application for glaucoma education in the south bronx

Conditions: Glaucoma

Summary: a team at the national healthcare group eye institute in singapore have developed an augmented reality mobile phone application, eyecu, to simulate glaucoma progression and enhance understanding about the disease and its course. it is a bilingual (english/spanish) application that is free-to-download on the android and apple app store. as eye care physicians in the south bronx, the investigators are hopeful that the findings in this study can be extrapolated to our patients in the south bronx, where poor health literacy, non-adherence to glaucoma medication and poor follow-up remains a large barrier. the investigators hope that by offering the simulation in both english and spanish, the investigators will not only be able to improve our patients' understanding of glaucoma, but also improve glaucoma treatment adherence and assess our patient population's responsiveness to augmented reality as an educational platform.

experimental design: pilot cohort study data collection: patient characteristics such as age, sex, ethnicity, preferred language, zip code, employment status, highest educational attainment, current topical eye medications, past ocular history, past medical history recruitment for participation in the study will be performed during glaucoma clinic registration consent will be conducted by a member of the research team who is not directly involved in the participant's clinical care pre-intervention glaucoma knowledge questionnaire (nehep glaucoma knowledge questionnaire) will be given to participants, to be completed on dedicated clinic tablet device. post-intervention glaucoma knowledge questionnaire (nehep glaucoma knowledge questionnaire) will be given to participants, to be completed on dedicated clinic tablet device. rate of missed glaucoma follow-up appointments before and 6 months after application use will be collected from the electronic medical record. rate of medication adherence before and 6 months after application use will be collected from the electronic medical record.

Eligibility criteria:
inclusion criteria: - patients with a clinical diagnosis of glaucoma on medical therapy for at least 4 months exclusion criteria: * patients with optic neuropathies unrelated to glaucoma * patients with va 20/100 or worse in both eyes * visual defects involving fixation in both eyes * patients with symptoms impairing ability to operate a smartphone during visit including diplopia, motor difficulties, cognitive impairment, illiteracy * patients who are unable to read or understand english or spanish
the validity and reliability study of turkish version of the sense of competence in dementia care staff (scids) scale

Conditions: Dementia

Summary: the purpose of the study is to adapt the scids into the turkish version and validate it in the social and cultural context of turkey to assess staff competency in dementia care in the long-term care setting.

most existing tools measuring care adequacy are targeted at family caregivers. tools targeting formal dementia carers have focused primarily on dementia care knowledge, care attitudes and care workloads separately. there is less research investigating the assessment of competence in dementia care among formal healthcare staffs. there is no validated tool to accurately assess staff competency in dementia care in the long-term care setting in turkey. schepers et al. developed a scale dedicated to assessing sense of competence in dementia care staff, including relationship building, maintaining personality, professionalism, and care challenges. today, the scale has been used to evaluate the effectiveness of training programs and has demonstrated its applicability.

Eligibility criteria:
inclusion criteria: * working as a dementia care staff for at least 1 year exclusion criteria: * not volunteering

Keywords: dementia turkish version dementia care staff sense of competence in dementia care staff scale validity reliability
comparative low and high dose of dexmedethomidine in pituitary tumor removal by transphenoid approach

Conditions: Pituitary Tumor

Summary: transnasal transsphenoidal (tnts) resection of pituitary tumors involves wide fluctuation in hemodynamic parameter and causes hypertension and tachycardia due to intense noxious stimuli during various stages of surgery. none of routinely used anesthetic agents effectively blunts the undesirable hemodynamic responses, and therefore usually there is a need to use increased doses of anesthetic agents. dexmedetomidine (dex) an α-2 adrenergic receptor agonist, because its sympatholytic and antinociceptive properties may ensure optimal intraoperative hemodynamic stability during critical moments of surgical manipulation. in addition, dex reduced the anesthetic requirement with rapid recovery at the end of surgery. the main aim of the study was to evaluate the effect of dex on perioperative hemodynamics, anesthetic requirements

dex as an anesthetic adjuvant improved hemodynamic stability and decreased anesthetic requirements in patients undergoing tnts resection of pituitary tumor. in addition, dex provided better surgical field exposure conditions and early recovery from anesthesia

Eligibility criteria:
inclusion criteria: 1. age18-65 2. asa 1-2 3. elective tnts resection of pituitary tumor 4. no narcotic before surgery as premedication 5. able to extubate exclusion criteria: 1. gcs less than 15 2. preoperative heart rate less than 50 beat/min 3. no beta-blockers 4. pregnant patients 5. take any alpha-methyldopa, clonodine, other alpha-2 adrenergic agonist 6. hemodynamic unstable 7. systolic bp more than 160mmhg 8. cad 9. renal insuffuciency 10. allergy in dexmedethomidine and opioid 11. bmi more than 30 12. denied consent

Keywords: dexmedethomidine
a long-term follow-up study to evaluate the impact of lumicitabine on the incidence of asthma and/or wheezing in infants and children with a history of respiratory syncytial virus infection

Conditions: Respiratory Syncytial Virus Infections

Summary: the purpose of this long-term follow-up (ltfu) study is to evaluate the incidence of the clinical diagnosis of asthma and the frequency of wheezing in infants and children with respiratory syncytial virus (rsv) infection who were treated with (lumicitabine or placebo) and have completed their last planned study-related visit in a feeding phase 2 study (64041575rsv2004).

rsv is a leading cause of lower respiratory tract disease in infants. the primary hypothesis is that treatment of rsv-infected infants/children with lumicitabine (also known as jnj-64041575 or als-008176) will decrease subsequent wheezing/asthma compared to placebo (looks like lumicitabine). the participants who have completed treatment course (lumicitabine/placebo) and last study visit in a previous study, 64041575rsv2004, for the treatment of rsv infection will be enrolled in this ltfu study. the main purpose of this study is to understand the impact of lumicitabine on the occurrence of asthma/wheezing in infants/children with a history of rsv infection. the participants will be assessed via monthly calls with the parents/caregivers and also at site visits at 3, 6,12 and 24 months.

Eligibility criteria:
inclusion criteria: * male or female infants and children who were previously randomized in study 64041575rsv2004 for the treatment of respiratory syncytial virus (rsv) infection and who completed the planned course of the study drug and the last study-related visit of study 64041575rsv2004 * the participant's legally acceptable representative must sign an informed consent form (icf) indicating that he or she understands the purpose of, and procedures required for, the study and is willing for the participant to participate in the study exclusion criteria: * the participants legally acceptable representative, i.e, parent/legal guardian/caregiver, is not able to maintain reliable communication with the investigator * any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
study of controlled release formulations of ce-224,535 against the immediate release formulation in normal volunteers

Conditions: Rheumatoid Arthritis

Summary: this study is to test the idea that a controlled release formulation of ce-224,535 may allow for less frequent dosing and exposure to lower levels of drug than an immediate release formulation.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ecg and clinical laboratory tests). * body mass index (bmi) of 18 to 30 kg/m2; and a total body weight \>50 kg (110 lbs). a bmi lower limit of 17.5 kg/m2 may be rounded up to 18.0 kg/m2; a bmi upper limit of 30.5 kg/m2 may be rounded down to 30.0 kg/m2 and will be acceptable for inclusion. * an informed consent document signed and dated by the subject or a legally acceptable representative. * subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at screening. * any conhistory of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of hard liquor) within 6 months of screening. * condition possibly affecting drug absorption (eg, gastrectomy).

Keywords: pharmacokinetics immediate release oral suspension controlled release formulation
woodsmoke exposure and cardiovascular function

Conditions: Respiratory Inflammation; Systemic Inflammation

Summary: air pollution is linked to respiratory and cardiovascular disease. wood smoke is a common air in many parts of the world and previous studies indicate that wood smoke induce oxidative stress in the respiratory tract. it is not determined how different types of biomass combustion affect human health. in this study the investigators plan to investigate how inhalation of wood smoke and pellets smoke affect respiratory and cardiovascular health.


Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: * use of regular medication except the oral contraceptive pill * current smokers * significant occupation exposure to air pollution * intercurrent illness

Keywords: wood smoke inflammation lung function arterial stiffness heart rate variability respiratory and systemic inflammation following exposure to woodsmoke in healthy volunteers
phase iv clinical trial to evaluate efficacy and safety of masi bone s (alendronate sodium trihydrate) in postmenopausal women with osteoporosis

Conditions: Osteoporosis

Summary: this study aims to prove non-inferiority of the efficacy of masibone s (alendronate sodium trihydrate 70mg, oral solution) on the treatment of postmenopausal osteoporosis compared to the efficacy of fosamax (alendronate sodium 70mg, oral tablet). the effect of masibone s and fosamax on bone mineral density in postmenopausal women with osteoporosis will be compared and analyzed. this study included a total 170 patients (85 per subgroup) for multi-center, randomized, open-label, parallel clinical trial. the drugs will be maintained for a total of 48 weeks. the primary endpoint is the difference of bone mineral density change at lumbar spine measured by dexa between two groups.


Eligibility criteria:
inclusion criteria: 1. postmenopausal women ≥50 years old 2. osteoporosis - bmd t-score ≤-2.5 at lumbar spine, femoral neck, or total hip within previous 24 weeks - bmd t-score -1.0\~-2.5 at lumbar spine, femoral neck, or total hip within previous 24 weeks and history of osteoporotic fractures - bmd t-score -1.0\~-2.5 at lumbar spine, femoral neck, or total hip within previous 24 weeks and frax mof \>20% or hf \>3% 3. those who voluntarily agree in written form to participate in the clinical trial after hearing the explanation of this clinical trial and those who do not have any of exclusion criteria exclusion criteria: 1. patient with history of drugs that affect bone mineral density - bisphosphonate, denosumab, teriparatide, romosozumab within one year - calcitonin or analogues, calcimimetics within previous 12 weeks - strontium or fluoride for treating osteoporosis at any time in the past 2. patients with history of osteonecrosis of jaw, osteonecrosis of external ear canal, or atypical femoral fracture 3. patients with history of invasive dental procedure (tooth extraction, implant, oral surgery etc) within previous 24 weeks or patients who plan for invasive dental procedure during the clinical trial period 4. patients with risk of aspiration (esophageal disorders such as esophageal stricture, achalasia or patients who can not sit or stand for more than 30 minutes) 5. patients with severe renal dysfunction (egfr by mdrd \<30 ml/min/1.73m2 or on dialysis) or liver dysfunction (ast or alt ≥x3 upper limit of normal reference range) 6. patients who are under treatment or plan for treatment due to solid tumor or hematologic malignancy 7. patients with secondary osteoporosis (persistent systemic steroid use, uncontrolled hyperthyroidism, primary hyperparathyroidism) 8. hypocalcemia (albumin-corrected calcium \<2.1mmol/l) or vitamin d deficiency (25ohd \<10ng/ml) during screening 9. patients with known allergic reaction, hypersensitivity, or intolerance to bisphosphonate and other components of intervention drugs during screening (including latex allergy and hereditary fructose intolerance) 10. patients who the examiner considers not eligible for clinical trials
microbial and human determinants of the onset of ibd flares

Conditions: Ulcerative Colitis; Crohn Disease; Irritable Bowel; Crohns Disease Aggravated; Crohn Disease in Remission

Summary: this is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of ibd flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata. this study is direct to participant and will not utilize clinical sites.

this is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of ibd flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata. this study will last approximately 3 years and will recruit up to 1000 crohn's disease participants and up to 1000 ulcerative colitis participants that will participant in the study for approximately 12 months. participants will be sent at home sample collection kits and a study survey each month. if the survey responses indicate a participant is in a flare, they will be sent a sample collection kit and survey on a weekly basis until the flare is over and the monthly schedule resumes. the objective of the data analysis is to identify microbial functions that are predictive of the onset of a flare.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * able to provide written informed consent prior to screening * established diagnosis of small bowel or colonic crohn's disease (cd) or ulcerative colitis (uc) exclusion criteria: * pregnant or breastfeeding * use of antibiotics within the last 3 months * bowel surgery in the past 3 months or planned bowel surgery during the 12-month study period

Keywords: ibd flare uc cd hbi sccai stool diarrhea abdominal pain inflammation colon rectum
reducing fall risks for adults with obesity

Conditions: Obesity; Bariatric Surgery Candidate; Gait, Unsteady

Summary: the objective of the clinical study was to examine if practice could improve walking patterns associated with fall risks before patients with obesity underwent weight loss surgery. we hypothesized that patients would show improvements in their walking after completing the intervention. for the intervention, patients walked under five conditions: on flat ground at the beginning of the study, crossing three obstacle heights, and on flat ground at the end of the study for a total of 25 times.

obesity has a negative impact on aspects of walking associated with fall risks. after weight loss surgery, adults show improvements in walking. however, those who undergo surgery still show deficits in walking and an additional group of individuals do not undergo the procedure. our objective was to examine if practice could improve gait patterns associated with fall risks before patients underwent weight loss surgery. adults with obese body mass index between 30 to 60 years old who were eligible to undergo the roux-en-y weight loss surgery procedure walked under five conditions: initial baseline walking on flat ground, crossing three obstacle heights, and final baseline walking on flat ground for a total of 25 trials. spatio-temporal gait parameters were collected using a gait carpet and body-worn sensors. the gaitrite mat was a 4.9 m long x 0.6 m wide pressure-sensitive mat with a temporal resolution of 120 hz and a spatial resolution of 1.3 cm. legsystm includes five wearable sensors containing triaxial gyroscopes, accelerometers, and magnetometers. dependent variables selected included velocity (cm/s), cadence (steps/minute), step length (distance between consecutive steps), step width (lateral distance between feet), single limb support time (amount of time spent on one leg during the walking cycle), and double limb support time (amount of time spend on two legs during the walking cycle).

Eligibility criteria:
inclusion criteria: * between 30 and 60 years old * eligible to undergo roux-en-y gastric bypass surgery * walk independently without assistive devices exclusion criteria: * scheduled to undergo knee surgery * receiving dialysis * being treated for cancer

Keywords: obesity gait bariatric surgery walking obstacles